Research Article
Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience
Table 3
Treatment received and outcomes.
| Stage | Number of patients (percentage) | Median overall survival (mOS) | Range of survival |
| Stage I | | 0 | 0 |
| Stage II | | 43 m | 18–60 m |
| Stage III | | 12.5 m | 6–30 m |
| Stage II and stage III | ; (46.5%) | | | (1) Upfront surgery | | 19.75 m | 6–60 m | (THE/TTE Cth) | (2) NACT + surgery | | 16 m | 14–18 m | (3) Cth/LAR; no Surgery | | 8.75 m | 6–13 m |
| Stage IV | ; (53.5%) | | | (1) Cisplatin + etoposide (G3) | | 6.5 m | 1.5–32 m | (2) Octreotide LAR (G2) | | 16 m | |
|
|